Dosing, Tolerability, and Formulary Impact: Aripiprazole and Quetiapine XR in MDD

In this episode, "Dosing, Tolerability, and Formulary Impact: Aripiprazole and Quetiapine XR in MDD," the mental health experts explored the following questions:

Aripiprazole was the first antipsychotic to receive FDA approval for adjunctive major depressive disorder (MDD) treatment, in 2007. What did the pivotal trials establish about its efficacy, and how has nearly two decades of clinical experience with aripiprazole shaped how the class as a whole is understood?

Quetiapine XR has a distinct pharmacologic profile from the dopamine partial agonists. What does the evidence show for its efficacy as adjunctive therapy, and what are the tolerability trade-offs, particularly around sedation and metabolic effects, that affect its clinical positioning?

Quetiapine is associated with greater weight gain and metabolic burden than several comparators — how does that factor into formulary placement decisions?

The panelists examined aripiprazole's pivotal trial design, which used an antidepressant lead-in phase followed by randomization to placebo or active drug among non-responders, with Thase detailing how dose-finding evolved toward lower 5 mg and 10 mg doses to minimize akathisia, the primary dose-limiting side effect, while preserving antidepressant benefit at doses lower than those used for antipsychotic indications. Wilkinson then reviewed quetiapine XR's distinct profile, noting it carries the highest sedation and metabolic risk among the five adjunctive agents, was studied primarily at 150 mg and 300 mg doses with the higher dose rarely tolerated, and delivers response rates near 60% despite high placebo response diluting signal detection in some analyses. Bhide added that formulary placement decisions weigh this efficacy-tolerability trade-off through broader therapeutic class reviews assessing both safety and efficacy together.

Throughout the conversation, the experts provided a comprehensive reflection on the field and the factors that may shape how clinicians approach care moving forward.

The next episode in this series, "Newer Agents, New Advantages: Brexpiprazole, Cariprazine, and Lumateperone in MDD," features the panelists advancing their conversation on major depressive disorder and focusing on brexpiprazole's improved tolerability through lower starting doses, cariprazine's D3-preferring mechanism and favorable metabolic profile, and lumateperone's distinguishing lack of weight gain as the newest agent in the class.